PDGFRB and lymphoid neoplasm: The current 2017 WHO classification recognizes the following specific diseases: M/LNs-Eo with rearrangements of PDGFRA, PDGFRB and FGFR1 respectively and the provisional entity of myeloid/lymphoid neoplasms with PCM1-JAK2 rearrangement [1].